ENT2 CRISPR/Cas9 KO Plasmid (m): sc-419988
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ENT2 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the ENT2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: ENT2 Antibody (D-9): sc-373871
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ENT2 CRISPR/Cas9 KO Plasmid (m) | sc-419988 | 20 µg | $397.00 |
Overview
Slc29a2 encodes equilibrative nucleoside transporter 2 (ENT2), a broadly expressed plasma membrane transporter that mediates bidirectional, concentration-dependent flux of purine and pyrimidine nucleosides such as adenosine and inosine. ENT2 helps regulate nucleoside salvage pathways, intracellular nucleotide pools, and extracellular adenosine homeostasis, thereby influencing DNA/RNA synthesis, cellular energetics, and purinergic signaling. In mouse systems, altered ENT2 activity is relevant to studies of metabolic stress responses, immune and inflammatory signaling driven by nucleoside availability, and transporter-mediated modulation of drug and nucleoside analog uptake. Slc29a2 is therefore frequently examined in contexts linking nucleoside transport to proliferation, differentiation, and tissue homeostasis.
ENT2 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Slc29a2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Slc29a2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Slc29a2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ENT2 protein expression.
This CRISPR knockout system enables efficient generation of Slc29a2-deficient cell models for investigation of ENT2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Slc29a2 exon(s) critical for ENT2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Slc29a2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by ENT2 CRISPR/Cas9 KO Plasmid (m) and ENT2 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Slc29a2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by ENT2 HDR Plasmid (m) and ENT2 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Slc29a2 homology arms to support homology-directed repair at defined Slc29a2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.